Dystrophic heart failure blocked by membrane sealant poloxamer. - Wikidata - wikimedia - TriplyDB

Dystrophic heart failure blocked by membrane sealant poloxamer.

Dystrophic heart failure blocked by membrane sealant poloxamer.

http://www.wikidata.org/entity/Q46604988

about

Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy Hierarchical accumulation of RyR post-translational modifications drives disease progression in dystrophic cardiomyopathy Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy The membrane-active tri-block copolymer pluronic F-68 profoundly rescues rat hippocampal neurons from oxygen-glucose deprivation-induced death through early inhibition of apoptosis Apoptosis repressor with a CARD domain (ARC) restrains Bax-mediated pathogenesis in dystrophic skeletal muscle Prevalence and distribution of regional scar in dysfunctional myocardial segments in Duchenne muscular dystrophy.Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype.Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy.Axial stretch of rat single ventricular cardiomyocytes causes an acute and transient increase in Ca2+ spark rate X-ROS signalling is enhanced and graded by cyclic cardiomyocyte stretch.Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy Structural and functional recovery of electropermeabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188.Gene printer: laser-scanning targeted transfection of cultured cardiac neonatal rat cells.Functional substitution by TAT-utrophin in dystrophin-deficient mice.The dystrophin complex controls bk channel localization and muscle activity in Caenorhabditis elegans.Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs.Differential effects of commercial-grade and purified poloxamer 188 on renal function Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.Role of dystrophin in airway smooth muscle phenotype, contraction and lung function.Subcellular Ca2+ signaling in the heart: the role of ryanodine receptor sensitivity.Effects of PEO-PPO-PEO triblock copolymers on phospholipid membrane integrity under osmotic stress Ex vivo stretch reveals altered mechanical properties of isolated dystrophin-deficient hearts.Mouse intact cardiac myocyte mechanics: cross-bridge and titin-based stress in unactivated cells.Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.Lengthening-contractions in isolated myocardium impact force development and worsen cardiac contractile function in the mdx mouse model of muscular dystrophy.Beta-blockers, left and right ventricular function, and in-vivo calcium influx in muscular dystrophy cardiomyopathy.One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice.Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.A high-throughput model of post-traumatic osteoarthritis using engineered cartilage tissue analogs Early right ventricular fibrosis and reduction in biventricular cardiac reserve in the dystrophin-deficient mdx heart.Poloxamer [corrected] 188 has a deleterious effect on dystrophic skeletal muscle function.S100 and annexin proteins identify cell membrane damage as the Achilles heel of metastatic cancer cells.Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex.SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice

P2860

Q24295360-DB0E3E41-194C-4FB7-BB03-87E7A92D9644 Q24306846-2083DE2E-C4E0-4804-BFC5-E6EE562C4405 Q24655319-9BC088B0-D5A0-4F72-9406-90A88DD72E07 Q24655371-A63169BD-34C0-4F50-B4BB-4D62A2180B7E Q27667441-66A7F4CD-44F2-434C-99EC-51E994ECFFCE Q28082625-E2DF0862-4D84-447F-B9C1-ADCCD70EBF4B Q28386144-697AF80B-E7FA-4252-BC5A-8F75873467F1 Q28511114-AAFE1AEE-5901-4E1F-B3A7-8FBC1DF89A9C Q30432693-F6175252-A42B-44D0-AB2D-26EA1E298C50 Q30493760-BD88F56D-BD04-4631-B82A-5693D87024CF Q30524974-E4492768-E4FF-4D89-92E6-9C3BC1A01BC3 Q30529903-1D23ED4E-1954-4277-B54E-BE051D2F45E7 Q30539103-6FC7A773-A04A-47DA-9664-C5C2535B71E2 Q30545559-DFD6735B-B7CD-4C03-83C7-663B57F77305 Q31106750-35129AA4-CE1B-4729-875D-B735194B0E3C Q33254358-D1E02DA5-3E54-48A0-BE1C-E2E7504AE153 Q33455443-A24914C1-68F5-4F67-9CEA-F67FDA61CC33 Q33519519-547D27BA-041A-4E49-BC96-C308FD95DAC8 Q33608478-9FDA4799-26DE-4B10-B374-05D60EF053E8 Q33755416-05339090-387D-4F41-B6FA-67F3E50484FF Q33804760-943E6CDA-FEDA-47CE-B4B4-A1341F15678D Q33901556-835A98FE-A595-4F19-9E26-DFDDB22216F5 Q33939933-21CCE48B-FA29-490C-8D7C-BD9148C9D10D Q34028253-F944DC1D-D17B-4136-81CA-CE6AE198A022 Q34087123-EDDEDC6C-6C8E-4C4C-94D1-1855C2016538 Q34200139-30704D30-C21E-4CD3-9B6B-E848D9A65219 Q34439598-3AAD1DC1-1B0A-4D5E-925D-6113C96B4408 Q34508301-7EC20343-761E-4AB9-8DE4-633137156D21 Q34598590-8903667B-36FF-4C37-9D4D-31DCDFB18B21 Q34600310-BD77485A-34BB-4F3C-850B-8BBD7572614A Q34621772-834CA5CF-73B5-4EBF-A8E2-3EDF7545E02D Q34737660-243DE386-AFC5-4155-A4EB-9D408A63A359 Q34981147-48BF4A85-52E4-4109-A73E-EBEB3FE558F4 Q35037292-8B576CF0-9721-488D-B08D-F34BE731C6A4 Q35086442-49093B54-11AA-454A-BFC2-5C9998E4E271 Q35123905-1C5B320E-B8FE-45DC-9DD4-76445D688EC3 Q35141257-47F45977-B3B8-4219-B2B4-F822075B37A7 Q35155971-0C9199F1-CCA6-42F8-AD51-88C621059A36 Q35169510-E86ADB9C-BC70-4B41-98A0-E8EA2BD6A61B Q35183186-E2929361-2438-4C30-993D-40FBCB150464

P2860

Dystrophic heart failure blocked by membrane sealant poloxamer.

http://www.wikidata.org/entity/Q46604988

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Dystrophic heart failure blocked by membrane sealant poloxamer.

@en

Dystrophic heart failure blocked by membrane sealant poloxamer.

@nl

type

label

Dystrophic heart failure blocked by membrane sealant poloxamer.

@en

Dystrophic heart failure blocked by membrane sealant poloxamer.

@nl

prefLabel

Dystrophic heart failure blocked by membrane sealant poloxamer.

@en

Dystrophic heart failure blocked by membrane sealant poloxamer.

@nl

P1433

Q46604988-F5ADC175-FB9C-47B1-86EC-C262A84AC680

P1476

Q46604988-F0D5C116-0E5B-4B12-8DE1-45D7D9E1462C

P2093

Q46604988-16D6C15C-6AE9-452B-82F8-DCD10EFCC26B

Q46604988-607D760E-F9D7-47C9-A417-E3798C8B1B5A

Q46604988-80D5A3D8-4707-411A-BD67-A4CC4CDBA9D7

Q46604988-EB2B1ACD-06B3-4E8A-8D79-1521D02AE33E

Q46604988-F236E117-F364-4367-BC61-600D7349C9BE

Q46604988-FD00E573-95E7-4A5F-8B5C-2646385B5143

P2888

Q46604988-1B30272E-CE5C-4CB6-B4FB-A720D4EB15F5

P304

Q46604988-2A95E521-7D5A-494B-9357-28AC52D492F2

P31

Q46604988-BA6CB7D0-9D86-4011-8AE7-98708DC0894D

P356

Q46604988-B686233A-E7C7-4F01-B5F9-A071CDFD2A9D

P407

Q46604988-7BFE0C3E-220B-44B9-8073-908907C2832B

P433

Q46604988-9D6386B8-1AAB-4EA9-BB61-3306F815A328

P478

Q46604988-FF048AA1-3119-4511-BB0D-8C3260A1C173

P577

Q46604988-D5214A17-D2F1-4A48-A1B2-4266CF730CE5

P5875

Q46604988-58F7A71F-1F7A-46C3-8B9F-CCF327109C05

P6179

Q46604988-F807B852-5653-489F-816F-177032FA4B9B

P698

Q46604988-0BEB7454-F087-41FC-8891-B2750A3806C7

P921

Q46604988-271C212B-E12B-4DBF-896B-8C866A4E5ED4

P356

P1433

P1476

Dystrophic heart failure blocked by membrane sealant poloxamer.

@en

P2093

Daniel E Michele

http://www.w3.org/2001/XMLSchema#string

DeWayne Townsend

http://www.w3.org/2001/XMLSchema#string

Elizabeth G Favre

http://www.w3.org/2001/XMLSchema#string

Joseph M Metzger

http://www.w3.org/2001/XMLSchema#string

Sharlene M Day

http://www.w3.org/2001/XMLSchema#string

Soichiro Yasuda

http://www.w3.org/2001/XMLSchema#string

P2888

P304

1025-1029

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE03844

http://www.w3.org/2001/XMLSchema#string

P407

P433

7053

http://www.w3.org/2001/XMLSchema#string

P478

436

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7719917

http://www.w3.org/2001/XMLSchema#string

P6179

1049868544

http://www.w3.org/2001/XMLSchema#string

P698

16025101

http://www.w3.org/2001/XMLSchema#string

P921